Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding by unknown
Conformational Changes Induced in the Human
Immunodeficiency Virus Envelope Glycoprotein by
Soluble CD4 Binding
By Q . J . Sattentau* and J. P . Moore$
From 'The Academic Department of Genito-Urinary Medicine, University College and
Middlesex School of Medicine, London WIN 8AA; and #Chester Beatty Laboratories, The
Institute of Cancer Research, London SW3 6,J$ United Kingdom
Summary
The human immunodeficiency virus (,HIV) binds to the surface of T lymphocytes and other
cells ofthe immune system via a high affinity interaction betweenCD4 and the HIV outer envelope
glycoprotein, gp120. By analogy with certain other enveloped viruses, receptor binding by HIV
may be followed by exposure of the hydrophobic NHZ terminus of its transmembrane
glycoprotein, gp41, and fusion of the virus and cell membranes. A similar sequence of events
is thought to take place between HIVinfected and uninfected CD4' cells, resulting in their
fusion to form syncytia . In this study, we have used a soluble, recombinant form ofCD4 (sCD4)
to model events taking place after receptor binding by the HIV envelope glycoproteins. We
demonstrate that the complexing ofsCD4 with gp120 induces conformational changes within
envelope glycoprotein oligomers. This was measured on HIV'-infected cells by the increased
binding of antibodies to the gp120/V3 loops, and on the surface ofvirions by increased cleavage
of this loop by an exogenous proteinase. At 37°C, these conformational changes are coordinate
with the dissociation ofgp120ACD4 complexes from gp41, and the increased exposure of gp41
epitopes . At 4°C, gp120 dissociation from the cell surface does not occur, but increased exposure
of both gp120/V3 and gp41 epitopes is detected. We propose that these events occurring after
CD4 binding are integral components of the membrane fusion reaction between HIV or
HIVinfected cells and CD4+ cells.
T
he CD4 molecule is found predominantly on the sur-
face ofT lymphocytes, where it functions as a coreceptor
for the T cell antigen receptor complex (1) . It has been sub-
verted by the human and simian immunodeficiency viruses
(HIV and SIV, respectively)' as their primary receptor (2) .
CD4 is a member of the Ig superfamily (3), with a structure
consisting of four extracellular Ig-like domains anchored to
the membrane by a hydrophobic segment, and followed by
a short cytoplasmic region (4), which interacts with p561`k,
an src-related tyrosine kinase (1) . The high affinity binding
site for the HIV outer envelope glycoprotein, gp120, is cen-
tered around a stretch of -12 amino acids in the first do-
main ofCD4, a region analogous to theCDR-2 loop of an
Ig tc light chain variable domain (5-10) . Several recent studies
have demonstrated that CD4 may have a more complex role
in initiating HIV infection of CD4' cells than simply
binding virus to the cell surface. The CDR-3-like loop of
the first domain o£ CD4 has been implicated in a step dis-
i Abbreviations used in this paper. sCD4, soluble CD4; SIV, Simian
immunodeficiency virus; WM, wash medium .
tinct from virus binding, which is important for membrane
fusion (11, 12), and CD4 antibodies have been characterized
that prevent virus infection and fusion of CD4+ cells with-
out inhibiting virus binding (13, 14) .
HIV entry into CD4+ cells is via a pH-independent
pathway, mediated in most circumstances by direct fusion
of the virus envelope with the cell membrane (15, 16), al-
though fusion in endosomes has also been reported (17, 18) .
The formation of giant cells (syncytia) by membrane fusion
between CD4' and HIV envelope-expressing cells is prob-
ably by a mechanism analogous to virus-cell fusion (19-22) .
The molecular interactions taking place after CD4 binding
that result inmembrane fusion are obscure. However, a soluble
form of recombinant CD4 (sCD4) has been shown to in-
duce the dissociation of gp120 from gp41 on the surface of
HIV virions or envelope glycoprotein-expressing cells (23-26).
Although there is no direct evidence linking this observation
with priming of a fusogenic mechanism, it may be that the
exposure ofcertain regions of gp41 after the binding ofgp120
to CD4 is an essential step in initiating fusion . Such a mech-
anism would be analogous to the exposure of the fusogenic
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conformational change in the outer envelope glycoprotein (27,
28) . Additional evidence supporting this hypothesis comes
from observations that at sub-inhibitory concentrations, sCD4
increases the infectivity of SIV andHIV2, and enhances fu-
sion of SIV or HIV-2-infected cells with CD4+ cells (29-31 ;
and P . Clapham, personal communication) . Thus, the com-
plexingofCD4 to theHIV/SIVenvelope glycoproteins may
directly activate the fusogenic mechanism of gp41, the final
stageofwhich probably involves insertionofthehydrophobic
NH2 terminus of gp41 into the host cell membrane (32-36) .
In this study, we have used sCD4 to model events taking
place when cell membrane-anchored CD4 interacts with
HIV-1 envelope glycoproteins.We report that sCD4 binding
induces conformational changes within envelope glycopro-
tein oligomers onHIVvirions and HIVinfected cells, resulting
in the increased exposure of regions of gp41 .
Materials and Methods
Monoclonal Antibodies.
￿
ThemAb Q4120 was prepared in our
laboratory, and reacts with the first domain of CD4 (14) . L120
was from D. Buck (Becton Dickinson Monoclonal Center Inc.,
San Jose, CA) and binds to domain 4 of CD4 (14) . mAbs 9284
(37) and 110.5 (38) react with different epitopes on the V3 loop
ofHTLVIIIB/gp120, and were obtained from DuPont Inc . (Wil-
mington, DE) and Genetic Systems Inc. (Seattle, WA), respectively .
The polyclonal anti-gp120 antiserum ABT 301 was from Amer-
ican Biotechnology Inc. (Cambridge,MA). D7324wasfrom Aalto
Bioreagents (Dublin, Ireland) and is an affinity-purified sheep an-
tiserum to a 15-amino acid peptide from the conservedCOOH
terminus ofgp120 isolate LAV1(39) .ThehumanmAbs 50-69and
98-6 were fromM. Gurney andS. Zolla Pazner (Veterans Adminis-
tration Association, NewYork) (40), and have been epitope mapped
by direct binding to synthetic peptides synthesized from gp41 of
HIV1/IIIB (M.K . Gomy andS. Zolla-Pazner, personal communi-
cation ; see Table 1) .
HIVinfected and Uninfected Cell Lines.
￿
ThehumanT cell lines
H9 andc8166 (fromM. PopovicandR. Gallo, National Institutes
of Health, Bethesda, MD) and H9 cells infected with HIV -1 iso-
late HTLVIIIB cloneHXB2 (fromR. Gallo) were grown inRPMI
1640 (Gibco Laboratories, Grand Island, NY) supplemented with
10% FCS (growth medium).
sCD4 Treatment AntibodyStaining, and Analysis ofCells.
￿
H9 cells
persistently infected with the HXB2 molecular clone of the IIIB
isolate were washed twice in RPMI/2% FCSwash medium(WM),
and resuspended at a concentration of 2 x 10' cells/ml . 50 g1 of
the appropriate concentration of sCD4 (from Smith, Kline, and
Beecham, King of Prussia, PA) (41) was added to 50 Pl of the cell
suspension . After 2 h or the appropriate length of time, the cells
were pelleted . The supernatants (100 Ftl) were removed, spun
through Spin-X 0.22-/Am filters (Costar, Cambridge, MA), mixed
with 10 ul of a 10% solution of NP40 in PBS-A, and frozen at
-20°C until assay. The cell pelletswere washed in 1 ml ofWM,
resuspended in 100 P .l of thesame buffer at 4°C, and 10 Al of cell
suspension (105 cells) was added to 10 P,l of each antibody. All an-
tibodies had been previously titrated and were used at saturating
concentrations. After a30-min incubation, the cells were washed
twice in WM, then 50 Pl of a dilution of the appropriate FITC-
labeled second layer antibody (either anti-mouse polyvalent Igs,
or anti-human IgG (Sigma Chemical Co., Poole, Dorset, UK) in
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WM was added . After 30 min, the cells were washed twice in
PBS-A/2% FCS, then fixed overnight in 200 'Al of a 1% solution
of formaldehyde in PBS-A . The fixed cells were analyzed by flow
cytometry on a FACScan® (Becton Dickinson&Co., Mountain
View, CA)using Consort 30 software. All antibody staining proce-
dures were carried out on ice. For some experiments, the sCD4
treatmentwasdone at 37°C,for others, at4°C . Where the results
are expressed as the mean fluorescence intensity, the background
staining (second layer only) has been subtracted .
ELISA for Detection of Soluble gp120 andp24 .
￿
Soluble gp120
and p24 in NP-40-inactivated cell supernatants were detected by
ELISA as previously described (24, 39, 42) .
Analysis ofgp120/V3 Loop Cleavage by Western Blotting .
￿
Virus
(HIV-1/111B), prepared as described previously (42), was analyzed
by acombination ofS-1000 gel exclusionchromatography andtwin-
site ELISA (24, 25, 42) . The total gp120 content of the culture
was 60 ng/ml, ofwhich -55% was present as virion-bound gly-
coprotein, the rest as soluble gp120 . An aliquot of this virus stock
(10 P,1) containing 600 pg of viral gp120 was incubated for 2 h
at 37°C with or without20 hg/mlofsCD4 and/or a1:20 dilution
ofmAb 110.5 ascitic fluid . After a further 2 h ofincubation with
100wg/ml of bovine thrombin (BoehringerMannheim Biochemi-
cals,Mannheim, Germany), the reactions were terminated byboiling
with 10 pl ofSDS sample buffer containing 2-ME . Proteins were
fractionated by electrophoresis on a 10% reducing SDS-polyacryl-
amide gel, then electrophoretically transferred onto nitrocellulose
(Schleicher& Schuell, Inc., Keene, NH) using a dry blotting ap-
paratus (Sartorius GmbH, Goettingen, Germany) . The filter was
blocked overnight with TBS containing20% FCS, 2% skimmed
milk powder (Cadbury's Marvel), and 0.5% Tween 20, then in-
cubated for 2 h in the same buffer containing a 1:2,000 dilution
of rabbit anti-gp120 (IIIB) antiserum RI/87 (a gift from R.S .
Daniels andJ.J . Skehel, MRC Research Centre, Mill Hill, UK) .
After extensive washing of the filters in TBS/0.1% Tween 20, bound
antibodies were detected with horseradish peroxidase-labeled sheep
anti-rabbit Ig (Seralab, Crawley, UK) and the ECL fluorometric
system (Amersham International, Amersham, UK).
Analysis ofgp120/V3 Loop Cleavage by Immunoassay .
￿
Virus stock
(25 Pl, as above) containing 1.5 ng of viral gp120 was incubated
for2h at 37°C with arange ofconcentrations ofsCD4 or preformed
sCD4-mAb complexes (see text) before addition ofbovine thrombin
(100 Erg/ml) to some samples for a further 1 h at 37°C (or in some
experiments for various times and temperatures ; see text) . The reac-
tions were terminated by addition ofEmpigen detergent to a final
concentration of1% (43) . The extracts were incubatedwith plastic-
adsorbed antibody D7324 to capture gp120 into the solid phase,
then reacted with mAb 110.5 as described previously (43) . This
antibody binds across the site ofthrombin cleavage in theV3 loop
and fails to bind to cleaved gp120 (43) . Consequently, cleavage is
detected by a reduction in 110.5 binding. Bound antibody was de-
tected with alkaline phosphatase-labeled rabbit anti-mouse Ig
(Dakopatts, High Wycombe,UK) andtheAMPAKsystem (Novo
Nordisk, Cambridge, UK) as described previously (39, 43) .
Results
sCD4 Binding to HIVinfected Cells Induces gp120 Dissocia-
tionfrom gp41 andExposesgp41 Epitopes. In this study, we
have used sCD4 to mimic the interaction of cell-anchored
CD4 withHIVenvelope glycoproteins expressedon the sur-
face of HIV-infected cells. We measured thebinding ofsCD4
to the cell surface, and the exposure of gp120 and gp41 epi-
CD4 Induces Changes in Human Immunodeficiency Virus Glycoproteins" Indicates amino acid residue numbers in minimum defined epitope of
HIV-1 clone HXB2 from the Los Alamos database .
topes using mAbs to these proteins in conjunction with im-
munofluorescent staining and flow cytometry. In initial ex-
periments, 10 jig/ml sCD4 was reacted with HIVinfected
cells at 37°C for 2 h before mAb staining. The formation
of sCD4/gpl20 complexes was monitored by the binding of
mAb L120 to the fourth domain ofCD4 (Table 1 and Fig .
1 a) . Before addition ofsCD4 to the cells, L120 staining was
at background levels, a consequence of CD4 downmodula-
tion by HIV infection (19) . The addition ofsCD4 increased
L120 reactivity by about fivefold over background (Fig. 1 a) .
As with L120, there was no significant binding ofQ4120
to the cell surface before sCD4 addition . However, unlike
L120, the addition ofsCD4 to the cells did not significantly
increase Q4120 reactivity (Fig. 1 b) . Since the epitope for this
mAb on domain 1 ofCD4 is masked in theCD4/gpl20 com-
plex (14), this experiment demonstrates that sCD4 is bound
to the cell by domain 1, implying that it interacts specifically
with gp120 rather than nonspecifically with the cell surface.
The polyvalent anti-gp120 antiserum ABT 301 reacted with
gp120 on the surface of the HIV-infected cells (Fig. 1 c) . A
small (2-10% in five separate experiments) decrease was ob-
served after the addition ofsCD4, suggesting that a minor
fraction of the total gp120 was lost from the cell surface on
CD4 binding (see Fig . 2 c and Discussion) . Similar data were
obtained with the D7324 antiserum to theCOOH terminus
of gp120 (data not shown), although this antibody stained
poorly, implying that the epitope was mostly obscured on
gp120 in its cell surface configuration . Before the addition
ofsCD4, the gp120/V31oopmAb 9284 reacted strongly with
the cells . After incubation with sCD4, however, 9284 staining
decreased by about twofold (Fig. 1 d) . Very similar results
were obtained with another gp120/V3 loop mAb, 110.5, reac-
tive with an adjacent but distinct epitope (data not shown) .
Two human mAbs that are specific for gp41 (50-69 and 98-6)
stained the cells in the absence ofsCD4, and showed a sub-
stantial increase in reactivity after the addition ofsCD4 (Fig .
409
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Figure 1 .
￿
HIVinfected H9 cells, treated or untreated with sCD4 for
2 h at 37°C were stained with some of the antibodies listed in Table 1
byindirectimmunofluorescence, and analyzedbyflow cytometry . The results
are expressed as overlayed histograms: (-) background staining with
the FITC-labeled second layer only ; (. . . . . . ) specific staining ofHIV1/
HXB2 infected H9 cells untreated with sCD4 ; and ( . . . . . . . . . ) specific staining
of infected H9 cells treated with sCD4 .
1, e andf) . mAb 50-69 stained more intensely than 98-6 both
before and after sCD4 binding.
To characterize further these observations,we investigated
the effect of sCD4 concentration on the staining of gp120
and the exposure of gp41 epitopes . Concentrations ofsCD4
ranging from 3.2 ng/ml to 50 NAg/ml were added to infected
cells for 2 h at 37°C, and the cells were stained as before .
As demonstrated by L120 staining, sCD4 binding increased
from virtually undetectable at the lowest sCD4 concentra-
tion, to maximal at 1 Ag/ml (Fig . 2 a) . Staining of gp120
with the V3 loop mAb 9284 initially rose as the sCD4 titer
increased, was maximal at -0.5 Ag/ml of sCD4, then fell
to about half the starting level (Fig. 2 a), consistent with
the results described in Fig. 1 d . In contrast to the biphasic
dose-response curve for V3 loop staining, the reactivity of
gp41 mAbs 50-69 and 98-6 increased substantially (about
fivefold and sevenfold, respectively) between 0.1 and 2 hg/ml
of sCD4 (Fig . 2 b), and did not then decrease.
Previous studies have shown that sCD4 induces gp120 dis-
sociation from gp41 (23-26) . In the current study, the con-
Table 1 .
Reagent
Antibodies
Origin
Used in this
Antigen
Study
Epitope Reference
L120 Mouse CD4 Domain 4 14
Q4120 Mouse CD4 Domain 1 14
9284 Mouse gp120 302-312`
(V3 loop) 37
110.5 Mouse gp120 307-317'
(V3 loop) 38
D7324 Sheep gp120 COOH
terminus 39
ABT 301 Rabbit gp120 Polyvalent
50-69 Human gp41 579-613 40
98-6 Human gp41 644-663 400
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Figure 2 .
￿
(a and b) HIV1/HXB2-infected H9 cells were treated with
varying concentrations of sCD4 for 2 h at 37°C before indirect im-
munofluorescence staining and analysis by flow cytometry. (c) The con-
centration of soluble gp120 released into the supernatant of the sCD4-
treated cells stained in a and b, as measured by ELISA .
centration of free gp120 in the supernatant increased with
the amount of sCD4 bound to the cell (Fig. 2 c) . To elimi-
nate the possibility that the increase in cell-free gp120reflected
sCD4-induced release of virions from the cell surface,we mea-
sured the amount of p24 in the supernatants . There was no
significant increase in the amount of soluble p24 at any sCD4
concentration (results not shown) .
sCD4 Binding to gp120 on HIVinfected Cells at 4°C Induces
Modulation ofAntibody Epitopes on gp120 and gp41 in the Ab-
Figure 3 .
￿
HIVinfected H9 cells, treated or untreated with sCD4 for
2 h at 4°C were stained with various antibodies byindirect immunofluores-
cent staining before analysis by flow cytometry. (a) The binding ofCD4
mAb L120, and represents the amount of sCD4 bound to the cell . (b)
The quantity ofsolublegp120 released into the supernatant from the same
cells . (cf) Staining with the following antibodies : (c), 9284 (gp120/V3
loop) ; d, D7324 (gp120/COOH terminus); e, 50-69 (gp41) ;f, 98-6 (gp41) .
Data are the mean of triplicate experiments, error bars are ± 1 SD.
sence of gp120 Dissociation .
￿
Because sCD4 binding causes
gp120 to dissociate from gp41 at 37°C, analysis of the con-
formational changes is complicated. However, at 4°C, the
sCD4-gp120-gp41 complex is stable (25) . We used this ob-
servation to investigate whether the binding ofsCD4 to gp120
on the surface ofHIVinfected cells induced epitope modula-
tion in the virus envelope glycoproteins in the absence of gp120
dissociation. The cells were saturated withsCD4 at 1 wg/ml
(Fig. 3 a), but there was no significant dissociation of gp120/
sCD4 complexes even at 10 wg/ml (Fig. 3 b) . Thus, any modu-
lation of HIV envelope epitopes induced by sCD4 is inde-
pendent of gp120 dissociation . Staining of gp120 with mAb
9284 (Fig. 3 c) increased coordinately with sCD4 binding,
reaching a maximum value of about twofold which was
achieved in the absence ofsCD4 . The same increase was con-
CD4 Induces Changes in Human Immunodeficiency Virus Glycoproteinssistently observed with 9284 in a number of experiments,
and also with the 110.5mAb (results not shown) . Therefore,
twice the number of gp120/V3 loop epitopes are available
for antibody binding in the presence of complexed sCD4 .
Staining with the polyvalent anti-gp120 antiserum also in-
creased in intensity after sCD4 treatment (results not shown),
suggesting either that this antiserum has substantial reactivity
with the V3 loop, or that regions ofgp120 additional to the
V3 loop become more accessible to antibody binding, or both .
In contrast to this, however, significant modulation ofD7324
staining was not observed after sCD4 complexing, demon-
strating that the conformational changes were not induced
globally (Fig . 3 d) . Both of the gp41 mAbs, 50-69 and 98-6,
stained the untreated infected cells at 4°C . After addition
of sCD4, the staining for both mAbs increased by twofold,
indicating a doubling in the number of exposed gp41 epi-
topes in the absence of gp120 dissociation (Fig. 3, e andfi .
Note that the increase at 37°C, where gp120 dissociation
occurs, was considerably greater (Fig. 2 b) .
sCD4 Binding to gp120 on Virions Increases the Exposure of
thegp120/V3 Loop to Proteolytic Cleavage. Using mAbs and
flow cytometry, we have demonstrated that sCD4 binding
induces epitope modulation in the V3 loop of gp120 on the
surface of infected cells. To confirm that similar changes take
place on matureHIV virions, we monitoredV3 loop exposure
by its susceptibility to cleavage by an endogenous proteinase,
thrombin (43) . In the sample ofvirus that we analyzed (HIV -
1/111B), approximately half of the gp120 present was on
virions, the rest was soluble protein . At 37°C, sCD4 addi-
tion caused a major proportion of the virion gp120 to dis-
sociate into the medium (24, 25) . This was unaffected by
thrombin. Thus, after sequential 2-h incubations at 37°C with
or without 50 Ag/ml sCD4 and 250 ug/ml thrombin added
v
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in either order, the percentages oftotal gp120 that were virion
bound were : virus alone, 57 ± 6% ; virus + thrombin,
59 ± 4% ; virus + sCD4, 24 ± 4% ; virus + sCD4 +
thrombin, 18 ± 3% ; virus + thrombin + sCD4, 20 ±
2% . At 4°C, sCD4 caused no significant loss of gp120 from
the virions within 2 h, and there was only a 10% reduction
in the amount of virion bound gp120 after 10 h (results not
shown) .
The basal rate of viral gp120 cleavage was low in the pres-
ence ofthrombin alone, but was greatly enhanced by the ad-
dition of sCD4 concentrations from 0.1 to 30,ug/ml (Fig.
4 a) . The sCD4-enhanced cleavage was blocked by prior ad-
dition of CD4 mAb Q4120, which competitively inhibits
gp120 binding to CD4 (14), but was unaffected byCD4 mAb
Q425, which inhibits HIV infection and syncytium forma-
tion at a step after gp120 binding (14) . Thus, the effect was
not due to a contaminant proteinase in the sCD4 prepara-
tion, but was a consequence of specific sCD4 binding. The
potentiating effect ofsCD4 onV3 loop cleavage was confirmed
by Western blotting ; thrombin cleavage of gp120 to 70- and
50-kD fragments was greater in the presence of sCD4 than
in its absence, and was completely inhibited by prior binding
of the HIVneutralizing mAb 110.5 across the cleavage site
(Fig . 4 b) . In addition, the rate ofvirion gp120 cleavage was
increased substantially in the presence ofsCD4 . It has been
shown elsewhere that thrombin cuts gp120 uniquely between
Arg-315 and Ala-316 in the V3 loop (43, 54) .
Both virion-bound and soluble gp120 are present in the
virus preparation. In principle, both are susceptible to pro-
teolysis by thrombin . However, when virions were separated
from soluble gp120 by gel exclusion chromatography (24,
42), then treated with thrombin (100 pg/ml) for 2 h at 37°C,
there was no significant loss of 110.5 binding to gp120 mea-
Figure 4 .
￿
(a) Supernatant containing
HIV1/IIIB was incubated with a range
ofsCD4 concentrations (0) or sCD4
preincubated with the CD4 domain 1
mAb Q4120 (O) or CD4 domain 3
mAb Q425 (0) for 2 h at 37°C,
followed by the addition of bovine
thrombin, or without thrombin but
with sCD4 (/) for a further 1 h . After
solubilization of the virions in deter-
gent, gp120 was captured to the solid
phase, and the binding of gp120/V3
loop mAb 110 .5 was monitored by
ELISA. Since :nAb 110.5 binds across
the site ofthrombin cleavage and cannot
bind to cleaved gp120, cleavage is de-
tected by a reduction in 110 .5 binding.
(b) Supernatant containing HIV-1/111B
was incubated at 37°C for 2 h with or
without sCD4 and/ormAb 110.5, then
with thrombin for a further 2 h at
37°C. The virions were solubilized in
SDS sample buffer, fi-actionated by poly,
acrylamide gel electrophoresis and ana-
lyzed by Western blotting. The figures
on the left sideofthe blot represent mo-
lecular masses in kilodaltons..o
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sured in a subsequent immunoassay (results not shown) . On
virions, gp120 is therefore resistant to thrombin cleavage. Thus,
the enhancement by sCD4 of thrombin cleavage ofviral gp120
might occur either by sCD4-induced conformational changes
in gp120 that increase the exposure of the V3 loop to pro-
teinases (as for recombinant gp120 ; 43) or by sCD4-induced
loss of gp120 from the virions (24, 25) increasing the con-
centration of soluble gp120 accessible to the proteinase, or
by a combination of these mechanisms . To address this, we
carried out a thrombin cleavage experiment at 4°C, in which
sCD4 binds to virions but does not cause gp120 dissociation
(25) . Under these conditions, sCD4 caused a clear enhance-
ment in the rate of cleavage of gp120, and eventually most
of the virion gp120 was cleaved despite about half remaining
on the virion . (Fig . 5) . Therefore, irrespective of any effect
of sCD4-induced increase in the concentration of soluble gp120
at 37° C, sCD4 binding to gp120 on the virion surface must
cause conformational changes in the viral envelope that in-
crease the accessibility of gp120 to an endogenous proteinase.
In the absence of sCD4, gp120 on the surface of the virion
is not significantly cleaved by thrombin: the tertiary/quaternary
structure of the envelope glycoprotein must preclude binding
of this proteinase.
Using sCD4 to mimic cell surface CD4, we havedemon-
strated that sCD4 complexing with the HIV envelope gly-
coproteins results in the modulation of antibody epitopes on
gp120 and gp41, and modulation of a proteolytic cleavage
site on gp120 .
The data that we have obtained at 37°C are complex, since
there are two phenomena occurring simultaneously : confor-
mational changes within an envelope glycoprotein oligomer
leading to increased exposure of certain epitopes, and shed-
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Figure 5 .
￿
HIV1/IIIB-containing supernatant was in-
cubated with or without 50 ftg/ml of sCD4 for 2 h at
either 4°C or 37°C, then thrombin added at the same
temperatures for various timesbefore solubilization of virus
and detection of cleaved gp120, as described for Fig . 4 a .
ding ofgp120 from the cell surface. AtlowsCD4 concentra-
tions, the increase in gp120/V3 loop mAb and polyvalent
antiserum binding to the cells is probably due to the epitope
modulation seen clearly at 4°C . The decrease in gp120 staining
with higher concentrations ofsCD4 probably represents gp120
loss superimposed onto the epitope modulation. The decreased
staining observed with the V3 loop mAbs at 37°C was con-
sistently greater than that with polyvalent antisera: this may
represent the labeling of a large proportion ofnonfunctional
gp120 molecules by the polyvalent reagents, or the masking
of V3 loop epitopes in addition to gp120 shedding .
At 4°C, in the absence of gp120 dissociation from gp41,
the increased binding of two mAbs to different epitopes of
the V3 loop of gp120, and the enhanced cleavage of this re-
gion by a proteinase, strongly suggest that this loop is more
exposed after sCD4 binding. This is in accord with results
obtained from proteinase cleavage of recombinant, soluble
gp120 in a previous study (43) . In contrast to the results ob-
tained at 37°C, no decrease inV3 loop staining was observed
at higher concentrations of sCD4 at 4°C . The increase in
binding ofV3 loop mAbs at 4°C was consistently found to
be about twice that in the presence of saturating concentra-
tions of sCD4 than in its absence. This approximate dou-
bling ofgp120/V31oop mAb staining was coordinate with
a twofold increase in the exposure of gp41 epitopes observed
under the same conditions . Several reports describe the orga-
nization ofHIV envelope glycoproteins into oligomers : the
bulk of the evidence suggests that the mature structure is
a tetramer (44-46), probably comprising two dimeric subunits
(46) . Our data may therefore represent the induction of a
conformational change within gp120/gp41 oligomers, a pro-
posal consistent with our previous report of the dynamics
of sCD4-induced gp120 dissociation from gp41 (25) . For ex-
ample, two gp120 molecules may interact within a dimer in
a nonsymmetric arrangement where the V3 loop on one mol-ecule is exposed, but on the other, hidden . Receptor occupa-
tion of the gp120 binding regions may flip the second loop
into an exposed state, destabilizing the oligomer . Thus, CD4
bindingmay modulate envelope glycoprotein epitopes by in-
ducing: (a) an allosteric change within individual gp120 mol-
ecules; (b) conformational changes between adjacent mole-
cules within an envelope glycoprotein oligomer ; or (c) both.
Previous studies have demonstrating that the V3 loop is
important for virus entry : antibodies to this region potently
block virus infection without interfering with gp120/CD4
binding (37, 38, 47, 48), and mutations in this region block
virus-cell fusion (49, 50) . The role of this region in HIV fu-
sion is not, however, understood . Itmaybe that the increased
exposure of theV3 loop after sCD4 binding allows its inter-
action with a cell surface molecule additional to CD4, such
as a cell surface proteinase, for which there is inferrential in
vitro evidence (43, 51-54) . Alternatively, exposed V3 loops
may interact with a second site on CD4, a proposal in accord
with the substantial downmodulation of V3 loop staining
after binding of sCD4 at 37°C (see Fig. 2 a) .
It is generally agreed that the NH2-terminal hydrophobic
domain of gp41 plays a critical role in membrane fusion
(32-36) . Direct evidence of the exposure of the fusion do-
main of gp41 is, however, currently lacking and will require
detection of this region immediately after sCD4 binding. Our
results from staining HIV-infected cells with gp41 mAbs
against two epitopes show that some regions ofgp41 are nor-
mally exposed on infectedH9 cells . This may be attributable
to the exposure of gp41 molecules that have lost gp120 spon-
taneously, or to the partial exposure of these epitopes in the
intact oligomeric gpl20/gp41 complexes. The increase in
staining after sCD4 binding may represent increased exposure
of gp41 epitopes as a result of any or all of the following :
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(a) conformational changes in gp41-associated gp120 mole-
cules ; (b) conformational changes within gp41 oligommes ; (c)
dissociation ofgpl20ACD4 complexes from gp41 . The two
epitopes on gp41 that we have studied do not correspond
to regions with known function . The mAb 50-69 recognizes
an immunodominant region that has previously been shown
to be highly conserved amongHIV-1 isolates (55), and struc-
turally conserved in many other retroviruses. Interestingly,
a peptide synthesized from a sequence directly adjacent to
the 50-69 epitope binds to a44-kD cell surface molecule, and
inhibits HIV infection ofCD4+ cells (56) . mAb 98-6 binds
gp41 nearer to theCOOH terminus, within a suggested a
helix (57) .
A rapid consequence of sCD4 binding to gp120 at 37°C
is the dissociation ofgp120 from gp41(23-26) . We have specu-
lated that this may be an initial step in the membrane fusion
process . It is clear from our present data that conformational
changes in the viral envelope can take place without dissocia-
tion of gp120 from gp41, albeit at4°C . Thus, complete sepa-
ration of the envelope glycoprotein subunits may not be a
prerequisite for the fusion reaction .
Although there are as yet no data demonstrating a direct
role ofCD4 in activation ofthe fusogenic mechanism inHIV
(57), there are observations of enhanced syncytium forma-
tion .and virus infectivity observed by us with certain strains
ofHIV-1 (QJ. Sattentau, unpublished results) and others with
SIV (29, 30) and HIV-2 (31; and P Clapham, personal com-
munication) when sub-inhibitory concentrations ofsCD4 are
added to syncytium or infectivity assays . Since such enhance-
ment can take place with CD4 - cells (P. Clapham, personal
communication), it may be that the role of CD4 in activa-
tion of HIV membrane fusion is as important as its role in
virus binding (58) .
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